4D Molecular Therapeutics’ adeno-associated virus gene therapy comprised of a transgene cassette encoding codon-optimzed human CFTR delta R was granted FDA orphan designation as a treatment of cystic fibrosis, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FDMT:
- 4D Molecular presents interim data from Randomized Phase 2 PRISM trial
- 4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
- 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
- 4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
- 4D Molecular receives RPDD from FDA for aerosolized 4D-710